Teva Canada Ranitidine Product Recall (2019-10-17)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
A. ACT-Ranitidine 150 mg Tablet;
| Lot or serial number | Brand name | Companies | DIN, NPN, DIN-HIM | Dosage form | Strength |
|---|
| K50175, K50944, K51170, K51171, K51172, K51173 | B. ACT-Ranitidine 300 mg Tablet | - Recalling Firm
- Teva Canada Limited
- 30 Novopharm Court
- Toronto
- M1B 2K9
- Ontario
- CANADA
- Marketing Authorization Holder
- Teva Canada Limited
- 30 Novopharm Court
- Toronto
- M1B 2K9
- Ontario
- CANADA
| DIN 02248571 | Tablet | Ranitidine 300 mg |
| K51136, K58444, K50205, K50860, K51114, K51139, K51141, K52964, K58446, K46486, K50593, K51071, K51076, K51144, K51146, K51148, K51150, K51152, K51154, K51164, K52965, K52966, K55591, K50203, K51069, K51132 | A. ACT-Ranitidine 150 mg Tablet | - Recalling Firm
- Teva Canada Limited
- 30 Novopharm Court
- Toronto
- M1B 2K9
- Ontario
- CANADA
- Marketing Authorization Holder
- Teva Canada Limited
- 30 Novopharm Court
- Toronto
- M1B 2K9
- Ontario
- CANADA
| DIN 02248570 | Tablet | Ranitidine 150 mg |
A. ACT-Ranitidine 150 mg Tablet;
B. ACT-Ranitidine 300 mg Tablet
Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).
Wholesalers, Healthcare Establishments, Retailers